Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy ; volume:7 ; number:1 ; day:12 ; month:4 ; year:2007 ; pages:1-9 ; date:12.2007
BMC cancer ; 7, Heft 1 (12.4.2007), 1-9, 12.2007

Urheber
Lee, Kyung-Hun
Beteiligte Personen und Organisationen
Im, Seock-Ah
Oh, Do-Youn
Lee, Se-Hoon
Chie, Eui Kyu
Han, Wonshik
Kim, Dong-Wan
Kim, Tae-You
Park, In Ae
Noh, Dong-Young
Heo, Dae Seog
Ha, Sung Whan
Bang, Yung-Jue
SpringerLink (Online service)

DOI
10.1186/1471-2407-7-63
URN
urn:nbn:de:1111-2016030343421
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:21 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Lee, Kyung-Hun
  • Im, Seock-Ah
  • Oh, Do-Youn
  • Lee, Se-Hoon
  • Chie, Eui Kyu
  • Han, Wonshik
  • Kim, Dong-Wan
  • Kim, Tae-You
  • Park, In Ae
  • Noh, Dong-Young
  • Heo, Dae Seog
  • Ha, Sung Whan
  • Bang, Yung-Jue
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma

A case of doxorubicin and cyclophosphamide therapy-induced type 1 diabetes: a case report

A case of doxorubicin and cyclophosphamide therapy-induced type 1 diabetes: a case report

Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer

Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer

Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells

Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells

Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells

Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells

Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant

Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant

Books received

Aufsatz

Books received

Catalogues received

Aufsatz

Catalogues received

Books received

Aufsatz

Books received

Books received

Aufsatz

Books received

Books received

Aufsatz

Books received

Books received

Books received

Verbundene Objekte